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Abstract
Background: Incidence of hepatitis C virus (HCV) induced hepatocellular carcinoma (HCC) has been increasing in
the United States and Europe during recent years. Although HCV-associated HCC shares many pathological
characteristics with other types of HCC, its molecular mechanisms of progression remain elusive.
Methods: To investigate the underlying pathology, we developed a systematic approach to identify deregulated
biological networks in HCC by integrating gene expression profiles with high-throughput protein-protein
interaction data. We examined five stages including normal (control) liver, cirrhotic liver, dysplasia, early HCC and
advanced HCC.
Results: Among the five consecutive pathological stages, we identified four networks including precancerous
networks (Normal-Cirrhosis and Cirrhosis-Dysplasia) and cancerous networks (Dysplasia-Early HCC, Early-Advanced
HCC). We found little overlap between precancerous and cancerous networks, opposite to a substantial overlap
within precancerous or cancerous networks. We further found that the hub proteins interacted with HCV proteins,
suggesting direct interventions of these networks by the virus. The functional annotation of each network
demonstrates a high degree of consistency with current knowledge in HCC. By assembling these functions into a
module map, we could depict the stepwise biological functions that are deregulated in HCV-induced
hepatocarcinogenesis. Additionally, these networks enable us to identify important genes and pathways by
developmental stage, such as LCK signalling pathways in cirrhosis, MMP genes and TIMP genes in dysplastic liver,
and CDC2-mediated cell cycle signalling in early and advanced HCC. CDC2 (alternative symbol CDK1), a cell cycle
regulatory gene, is particularly interesting due to its topological position in temporally deregulated networks.
Conclusions: Our study uncovers a temporal spectrum of functional deregulation and prioritizes key genes and
pathways in the progression of HCV induced HCC. These findings present a wealth of information for further
investigation.
Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer mortality in the world [1] and its
incidence has been increasing in North America, Europe
and Japan [2-5]. A recent study reported that approxi-
mately half of the observed increase in HCC is due to
hepatitis C virus (HCV) infection, whereas the incidence
of HCC related to other risk factors such as hepatitis B
virus (HBV), alcoholic liver diseases or idiopathic cirrho-
sis has remained stable [6].
Like other etiological factors such as HBV, HCV
induced HCC undergoes distinct histopathological
stages, including chronic hepatitis, cirrhosis, dysplasia
and eventually HCC [7]. Some genes were found to play
critical roles in these processes, including MMP9,
TIMP1 and STAT1 [8-11]. However, the spectrum of
temporal pathway deregulation has rarely been studied
using a systematic framework.
An approach for the examination of molecular events
accompanying HCV related HCC progression is to
leverage genome-wide technologies to search for
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deregulated genes and pathways in each pathological
stage. Despite the increasing use of next generation
sequencing in cancer studies [12,13], microarray gene
expression is still widely applied as a mature and cost
efficient technology [14,15]. For example, we recently
identified progressively silenced genes in liver neoplasm
transformation [16] and studied the functional roles of
HDAC3 and its cofactor NCOR1 [17] in HCC using
microarray data. In another recent study, 75 tissue sam-
ples representing stepwise HCV induced carcinogenesis
from normal liver to HCC were analyzed using the Affy-
metrix Human Genome U133 plus 2.0 array platform,
which identified gene signatures reflecting the pathologi-
cal progression of the disease at each stage [3].
In this study, we applied a network-based approach to
learn the specific molecular events underpinning the
development of HCV induced HCC. Instead of compar-
ing the gene expression profiles of two consecutive
stages, we overlaid gene expression data with protein
interaction networks (PIN) and identified representative
subnetworks for each pathological stage. We focused on
five stages including normal (control) liver, cirrhotic
liver, dysplasia, early HCC and advanced HCC. Our
resulting networks display the current biological knowl-
edge regarding hepatocellular carcinogenesis and malig-
nant transformation. We also found CDC2 (alternative
symbol CDK1, encoding cyclin-dependent kinase 1) to
be a critical gene in the continuous deregulation of the
cell cycle in HCC progression.
Methods
Data collection
Gene expression data was downloaded from Gene
Expression Omnibus (GEO) database [18]. Data set
GSE6764 [3] was used to identify networks in this study.
This data set includes 75 samples, including 8 distinct
pathological stages, but no other clinical information is
available for these samples. We excluded 3 samples
from cirrhotic liver tissue of patients without HCC. To
increase statistical power, we combined low-grade dys-
plastic nodules and high-grade dysplastic nodules as a
dysplastic group, early HCC and very early HCC as an
early HCC group, and advanced HCC and very
advanced HCC as an advanced HCC group. As a result,
5 groups were included in our analysis, i.e., normal, cir-
rhosis, dysplasia, early HCC and advanced HCC. Since
this data set had been already normalized when it was
submitted to GEO, no more normalization was per-
formed in our analysis. For genes with more than one
probe set in the array platform, we used the maximal
value in each sample to collapse those probe sets. Pro-
tein interaction data was downloaded from the Protein
Interaction Network Analysis (PINA) platform [19]. As
of 3/4/2010, the PINA platform contained 10,650
unique nodes and 52,839 edges. Each node represents a
gene product (i.e., protein encoded by the gene) and
each edge represents an interaction between the two
linked nodes. To verify our results, we downloaded
another independent microarray gene expression data-
set, GSE14323 [15] from GEO. This dataset includes
compatible normal and cirrhotic tissue samples, which
we used to verify our normal-cirrhosis network.
The HCV-host protein interaction data was down-
loaded from the Hepatitis C Virus Protein Interaction
Database [20] as of 7/10/2011. This database manually
curated 524 non-redundant HCV protein and host pro-
tein interactions from literatures. A total of 456 human
proteins were catalogued.
Algorithm
To construct a network for each stage, we weighted each
node in the protein interaction network by their expres-
sion fold changes (absolute value, log2 scale) between
consecutive groups and obtained a node-weighted pro-
tein interaction network for each stage. We then ranked
the genes by their weights and selected the top 500 genes
as seed genes. That is, we obtained a list of 500 deregu-
lated genes for each pair of consecutive stages (normal-
cirrhosis, cirrhosis-dysplasia, dysplasia-early HCC, and
early HCC-advanced HCC). We tested different numbers
of top ranked genes as seeds, and the resulting networks
were similar (data not shown). These genes were mapped
to the network and used to extract a vertex-induced sub-
network, referred to as the seed network, from the stage
specific network. It is worth noting that in practice these
500 genes may not be all present in the human interac-
tome (i.e., PINA network). Therefore, only genes mapped
in the whole human interactome were used as seeds. The
following process of network query employs an iterative
algorithm to expand the seed network, as was similarly
done in our recent work on dense-module searching of
genetic association signals (dmGWAS algorithm) from
the genome-wide association studies (GWAS) [21]. The
first step is to find the neighborhood node of maximum
weight within a shortest path distance d to any node of
the seed network. We chose d = 2 considering that the
average node distance in the human protein interaction
network is approximately 5 [22]. If the addition of the
maximum weight neighborhood node yields a score lar-
ger than a certain criterion, the addition is retained and
thus the network expands. This process iterates until no
additional node meets the criterion, thus, iteration termi-
nates. In each iteration, the seed network is scored by the
average score of all nodes in the current network. Incor-
poration of a new node must yield a score larger than
Snet × (1 + r) where r is the rate of proportion increment.
To obtain a proper r value, we set r from 0.1 to 2 with a
step size 0.1 to assess the performance of subnetwork
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construction. For each r value, we ran the searching pro-
gram and calculated the score of the resulting network.
The r value leading to the first maximal network score
was used as the final value of r. To avoid local optimiza-
tion, median filtering was applied to smooth the score
curve. According to our empirical observation, setting
the maximum r to 2 is sufficient because scores are maxi-
mized before this value is reached (see additional file 1).
The network was further refined by removing any com-
ponent with less than 5 nodes so that we could prioritize
more informative interacting modules. Eventually we
identified 4 networks, named the Normal-Cirrhosis net-
work, Cirrhosis-Dysplasia network, Dysplasia-Early HCC
network and Early-Advanced HCC network. The first
two networks are indicated as precancerous networks,
whereas the latter two as HCC cancerous networks.
Statistical significance test
We assessed network score significance with two tests.
1) We permuted the gene expression matrix by ran-
domly swapping class labels. For genes in the 4 identi-
fied networks, we calculated gene weights from the
random expression matrix and then determined a net-
work score from these random gene weights. Statistical
significance, denoted Prand, was computed as the pro-
portion of random scores that are larger than or equal
to the real score. Permutation trials were conducted
over 1,000 iterations. 2) We permuted gene labels on
the network so as to disrupt the correlation of gene
weights and interactions. Then, we used the same seed
genes to identify counterpart networks with identical
procedures. We compared real network scores with the
counterpart network scores to obtain Pperm. The permu-
tation trials were then conducted 100 times. We also
tested the significance of topological structure in these
networks. For each network, we generated 1,000 back-
ground networks with the Erdos-Renyi model [23,24].
Every background network has the same number of
nodes and edges as the real network. We compared
clustering coefficients of real networks with the back-
ground networks to obtain Ptopo.
Enrichment analysis
We conducted functional enrichment analysis for the
networks based on Gene Ontology (GO) Biological Pro-
cess terms [25,26]. Enrichment significance was deter-
mined by analyzing a hypergeometric distribution as
described previously [27]. P values were then corrected
for false discovery rate (FDR). Gene sets containing less
than 5 genes overlapping with the network were
removed from the analysis. In our HCC module map,
GO terms with an FDR-adjusted P-value of less than
0.05 in at least one network were retained.
Results
Overview of the networks and network connections
Following the sequence of normal, cirrhosis, dysplasia,
early HCC and advanced HCC, we identified a represen-
tative network for each stage (Figure 1 for major com-
ponent, Table 1). The full networks are provided in
additional file 2. These networks are highly significant in
terms of both score and topological structure measure-
ments (no random case outperformed the real case,
Prand < 1.0 × 10
-3, Pperm < 1.0 × 10
-2, Ptopo < 1.0 × 10
-3),
which can be explained by a high proportion of differen-
tially expressed genes (DEG) and hub proteins in the
networks. Here, a hub protein is defined to have more
than 5 protein interactions in those stage-specific net-
works. On average, DEGs account for 92.2 (± 5.4)% of
nodes. Hub proteins occupy only 14.8 (± 3.6)% of the
network nodes but are involved in 67.4 (± 10.0)% of
associations. The existence of these hubs suggests net-
work architecture being different from that of random
networks and implicates potential modules of interest in
these networks. Modules in biological networks often
represent molecular complexes and pathways [24,28]
which are the main objects of research in this study.
Although the four networks were identified indepen-
dently, they have connections in terms of included pro-
teins and interactions. As shown in Figure 2, the
Normal-Cirrhosis network, which consists of 55 pro-
teins, and Cirrhosis-Dysplasia network, which consists
of 38 proteins, have 16 proteins in common, while the
Dysplasia-Early HCC network (60 proteins) shares 17
proteins with Early-Advanced HCC network (68 pro-
teins). It is important to note that precancerous net-
works (Normal-Cirrhosis, Cirrhosis-Dysplasia) and
cancerous networks (Dysplasia-Early HCC, Early-
Advanced HCC) only have marginal overlaps. This poor
overlap suggests a dramatic difference of deregulation in
cancerous and precancerous liver tissues.
Verification of the representative network
There are two possible ways for verification. One is to
verify the robustness of expression patterns of the net-
work genes and the other is to verify the robustness of
the searching strategy. Due to the heterogeneity of avail-
able expression data on HCV induced HCC, we could
not find a single independent dataset including clinical
stage annotation to the extent of our experimental data.
However, it is feasible for us to use matched data for
the verification of specific networks. We used gene
expression data from GSE14323 [15] to verify our Nor-
mal-Cirrhosis network. This data set includes normal,
cirrhotic, and HCC tissue samples. To verify the expres-
sion patterns of the Normal-Cirrhosis network genes,
we mapped the genes to this dataset. As shown in
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Figure 3, 94.2% of the Normal-Cirrhosis network genes
display consistent expression changes in this additional
data set. To verify the robustness of the searching
approach, we used GSE14323 to identify Normal-Cir-
rhosis network following identical procedures. We
found that 58.2% of the original Normal-Cirrhosis net-
work genes are present in the verification network.
Most hub proteins identified in original network are
also hubs (degree > 5) in the verification network,
including CD44, CD74, VCAN and MMP2. This high
consistency indicates the reproducibility and reliability
of the Normal-Cirrhosis network. Although the other 3
networks could not be verified due to the lack of com-
patible data, the case of the Normal-Cirrhosis network
demonstrates that our approach can capture reproduci-
ble networks from gene expression data.
Figure 1 Giant component of each stage specific network. A, Normal-Cirrhosis network. B, Cirrhosis-Dysplasia network. C, Dysplasia-Early HCC
network. D, Early-Advanced HCC network. Nodes in the network represent genes and edges represent their interactions. Node colour is scaled to
gene expression fold change between two consecutive stages.
Table 1 Summary of the four networks
Network #Genes #Interactions #DEGs* #Hub
interactions†
Hub gene‡
Normal to cirrhosis 55 67 53 (96.3%) 42 (62.7%) LCK, CD44, CD74, COL1A2, MMP2, VCAN, STAT1, COL1A1
Cirrhosis to
dysplasia
38 50 37 (97.4%) 35 (70.0%) LCK, CD44, MMP9, COL1A1, PTPRC, MMP2, TGFB1
Dysplasia to early
HCC
60 65 53 (88.3%) 37 (56.9%) CDC2, MAD2L1, PRKCA, CDC20, NDC80, UBQLN4
Early to advanced
HCC
68 98 59 (86.8%) 79 (80.6%) CDC2, NDC80, PLK1, MCM2, AURKB, CCNA2, CDC20, AURKA, CCNB1,
NUF2, MMP9
*Differentially expressed genes (DEGs) were defined as genes with fold change ≥ 2 or ≤ 0.5 and student t test P value ≤ 0.01.
†Hub interactions refer to the total number of interactions involving hub genes.
‡Hub genes were defined to have at least 5 interactions in each network.
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Comparison of networks with HCV interacting proteins
All four networks comprise HCV binding proteins, as
was summarized in Table 2. It is interesting to note
that hub proteins are usually targeted, such as LCK,
STAT1 and VCAN in Normal-Cirrhosis network, LCK
in Cirrhosis-Dysplasia network, CDC2 and NDC80 in
Dysplasia-Early HCC network and Early-Advanced net-
work. HCV protein NS3 and NS5A seem to be actively
involved in these interactions. The non-structure pro-
tein NS3 is a processive DNA helicase [29] and was
suggested to associate with cancer related pathways
such as Notch pathway [30], caspase 8 induced apop-
tosis [31], etc. NS5A was reported to play functional
roles in immune invasion and carcinogenesis [32,33].
In a proteomic study, they were shown to co-regulate
focal adhesion in human cells [34]. Our results impli-
cate that these virus proteins could deregulate the core
cellular functions, e.g., immune responses and cell
cycle, by interacting directly with the hub proteins in
the molecular network. We speculate that such a hub-
targeting mechanism may represent a more effective
approach for viruses to invade host’s cellular
machineries.
Network functions suggest molecular events in HCC
progression
To understand these networks holistically, we applied
functional enrichment analysis based on the Gene
Ontology resource [25]. In total, 21 significant biological
processes (FDR ≤ 0.05) were prioritized. Distribution of
these processes varies for each particular network. We
compiled these processes into a single array, referred to
as the HCC module map, to learn the deregulation spec-
trum of HCC progression (Figure 4).
Figure 2 Comparison of network comprising genes. Numbers in
the cell represent the number of overlapped genes in two
networks. Colours are scaled according to the proportion of
overlaps.
Figure 3 Verification of Normal-Cirrhosis (NC) network in an independent data set. Row colour bar indicates expression changes of NC
genes in the experiment data. Pink red denotes up regulation in cirrhosis, blue denotes down regulation in cirrhosis. Column colour bar
indicates phenotype. Orange denotes normal samples and sky blue denotes cirrhotic samples.
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In the Normal-Cirrhosis network, which corresponds
to early stages of HCV infection, immune response,
MHC Type II activity, inflammatory response and cell-
cell signalling are enriched, indicating that a systematic
protection mechanism is activated in response to HCV.
Some cell adhesion genes are also up regulated in cir-
rhotic livers. These protection mechanisms seem
impaired in dysplastic livers, as is suggested by the
down regulation of immune response in our Cirrhosis-
Dysplasia network. Moreover, cell adhesion and signal
transduction are also down regulated, indicating the pre-
sence of more invasive and migratory hepatocytes in
dysplastic nodules [35].
A clear pattern in HCC networks (Dysplasia-Early
HCC network, Early-Advanced HCC network) is that
many more pathways are deregulated in the advanced
HCC network while the majority of pathways prioritized
in the early HCC network remain continuously up regu-
lated. These consistently deregulated pathways may play
critical roles in the transition from early HCCs to more
advanced stages considering their correlation to the
temporal order of HCC progression. Represented in this
group were cell cycle, cell division, and mitosis related
pathways (Figure 4).
Despite the consistency, the HCC module map dis-
closes a discrepancy in the Dysplasia-Early HCC net-
work and Early-Advanced HCC network related to
apoptosis. We examined apoptosis genes in these net-
works and found that gene ZBTB16 (encoding zinc fin-
ger and BTB domain containing 16, also known as
PLZF) has opposing expression patterns. That is,
ZBTB16 is up regulated in early HCC, and then down
regulated in advanced HCC. One function of ZBTB16 is
to prevent cell cycle progression [36] and suppress solid
tumorigenesis [37]. The expression pattern of ZBTB16
revealed in our study is consistent with those results
and indicates a role for loss of ZBTB16 expression in
HCC progression. Furthermore, strong negative
Table 2 Interactions between HCV proteins and network proteins
HCV protein Normal-Cirrhosis Cirrhosis-Dysplasia Dysplasia-Early HCC Early-Advanced HCC
CORE HLA-A, STAT1, VWF, DDX3Y VWF - -
NS5A LCK LCK CDC2 CDC2
NS3 VCAN FBLN1, EFEMP1, NID2, CTGF NDC80 NDC80
NS4A - - MT2A -
p7 - - UBQLN4 LMNB1
The HCV-host protein interaction data was retrieved from the Hepatitis C Virus Protein Interaction Database [20] as of 07/10/2011.
Figure 4 Functional enrichment of the networks to Gene Ontology terms of Biological Process. Colours were scaled by the average fold
changes of that gene set.
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correlation of its expression pattern with c-Myc was
observed (Figure 5B), indicating a possible regulation
mechanism between these two genes. Regulation of c-
Myc by ZBTB16 was previously reported in acute pro-
myelocytic leukemia cell line [36]. In HCC, for the first
time to our best knowledge, we show this regulation
sustains in cancerous stage, suggesting that it might be
a universal mechanism in carcinogenesis.
Networks prioritize genes and pathways in HCC
progression
One advantage of the network approach is that net-
works contain interaction information and visualization
of gene interactions provides an intuitive way to explore
gene functions in context. We present giant components
(the biggest connected subgraph) of the 4 networks in
Figure 1. These giant components account for 100.0%,
Figure 5 Evolution of CDC2 module in HCC progression. A, module overview in Dysplasia-Early HCC network and Early-Advanced HCC
network. B, expression profiles of CDC2 module genes in five pathological stages.
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84.2%, 51.7% and 91.2% of the network nodes,
respectively.
In the Normal-Cirrhosis network there are some
apparent module structures such as the MHC II com-
plex (major histocompatibility complex, class II), LCK
(lymphocyte-specific protein tyrosine kinase) signalling
module, chemokine gene module, etc. MHC II mole-
cules are antigen presenting proteins involved in cell-
mediated immunity, while LCK is a key regulator of T
cell activation and development [38-40]. Their up-regu-
lation suggests enhanced adaptive immunity responses,
which partially determine the outcome of HCV infection
[41]. Signalling molecule STAT1 was also a hub protein
in this network.
Adaptive immunity appears depressed considering the
overall down regulation of the LCK signalling module in
our Cirrhosis-Dysplasia network. Another module in
this network comprises extracellular matrix (ECM) regu-
latory and constituent genes, such as MMPs, TIMP2,
COL1A1, and COL1A2. TGF-beta 1, which was reported
to increase ECM production [42], is also included in
this module. Deregulation of this ECM related module
is strongly indicative of the aberrant morphology of dys-
plastic nodules, which are regarded as primary precan-
cerous lesions [14].
Unlike the LCK signalling module that shows oppos-
ing expression patterns in precancerous networks, the
CDC2 centered cell cycle module and MAD2L1 and
NDC80 centered spindle checkpoint signalling module
preserve their expression patterns in HCC networks.
Also the Early-Advanced HCC network includes a mini-
chromosome maintenance complex module and PLK1
(Polo like kinase 1) centered module, which are involved
in cell division [43,44]. Because of its role in cell prolif-
eration, PLK1 has been proposed as a potential thera-
peutic target in many cancers [45,46].
An important consensus of the HCC networks is hub
protein CDC2. CDC2, also known as CDK1 (cyclin
dependent kinase 1), is a key regulatory kinase of the
cell cycle [44]. We compared CDC2 modules from the
Dysplasia-Early HCC network and Early-Advanced HCC
network, and found that more deregulated genes are
involved in the latter (Figure 5A). Expression pattern
analysis indicates that the majority (86.7%) of the genes
whose encoded proteins interact with CDC2 in HCC
networks have continuously increasing expression dur-
ing carcinogenesis (Figure 5B). This pattern indicates
that this module is evolving towards a more deregulated
form in both size and extent during the progression of
HCC. A previous study has shown that the HCV core
protein perturbs both G1/S and G2/M phases of cell
cycle by up regulating the expression and activity of
cyclin B1-CDC2 complex [47]. Our network analysis
confirmed that finding. Furthermore, we show that
many more CDC2 interacting genes have concordant
expression profiles in HCC. This concordance suggests
that there might be some common regulatory mechan-
isms controlling the behavior of those closely associated
genes.
Although it remains unclear whether this module is
one of the driving forces for HCC malignancy, our
results implicate that by drug interference to this mod-
ule, HCC progression could be prevented to some
extent. Considering that CDC2 is a hub protein in the
network, its inhibition might be an effective way for
functional interference to this module. Further, CDC2 is
a kinase, which is a major druggable protein class
[48,49]. A pilot study reported that inhibition of CDC2
could decrease tumor growth and is a potential therapy
for hepatoblastoma tumor and some other tumors [50].
Our study, which provides further support for this treat-
ment strategy, suggests that a similar strategy may be
applied to HCV induced HCC for clinical therapy.
Discussion
In this study, we developed an integrative network
approach and applied it to study deregulated events in
HCV induced HCC. Unlike common pathway resources
such as KEGG biochemical pathways [51] or Gene
Ontology [25], we integrated microarray data with high
throughput protein-protein interaction data and
searched for deregulated networks during each patholo-
gical stage. Compared to pathways, networks give more
explicit protein interactions and provide flexible setting
of gene sets for investigation and, thus, facilitate genera-
tion of novel hypotheses.
Employing this approach, we attempted to dissect the
progression of HCV induced HCC. Findings in this
work not only confirmed many previous reports, but
also provided many novel and important insights. For
two examples, immune response was over-activated in
cirrhotic livers but then impaired in dysplastic nodules;
continuous up regulation of cell cycle and related pro-
cesses such as mitosis in HCC were detected by our
approach. Pivotal genes involved in these processes were
highlighted, including LCK, MMP genes, CDC2, etc.
Many cancer-related genes were also observed such as
CCNA2, AURKA, BIRC5 and GADD45B. We further
prioritized the CDC2 network module due to its evolu-
tionary pattern in HCC progression. To our best knowl-
edge, this is the first time that this module is
highlighted in a systematic manner in HCC studies.
Our data suggests that deregulations of these cellular
processes may result from direct HCV protein interac-
tions with the hub proteins in the molecular networks.
The most noticeable virus proteins in those interactions
are HCV non-structure protein NS3 and NS5A, both of
which were suggested to be potentially important for
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liver tumorigenesis [30-33]. Our finding that the HCV
proteins target the identified networks provides a sup-
portive argument on the utility and effectiveness of inte-
grative network approach to studying the molecular
mechanisms underlying complex diseases or traits.
There are several limitations in this study. First, the
complete human interactome data is still unavailable by
now, even though both the quantity (number of protein-
protein interaction pairs) and the quality (curation,
experimentally verified) of the data have been greatly
improved during the past years [19]. Second, findings
and conclusions in this work are derived from computa-
tional analysis and then are largely verified by literature
survey. Further functional and biological validation is
needed. Moreover, expression deregulation revealed by
microarrays may be limited because many genomic
alterations occur on different levels such as post-tran-
scriptional and post-translational levels and metabolic
level. It would be interesting to integrate those data in
future studies in order to reveal a comprehensive land-
scape of HCC pathogenesis at the molecular level.
Despite those limitations, our approach renders a
model to extract information from high throughput
genomic experiments. Our results show that such an
integrative method is promising to decipher complex
diseases, especially in front of current genome bio-
technologies such as microarray and whole transcrip-
tome sequencing (RNA-Seq by next generation
sequencing).
Conclusions
We developed an integrative network approach and
applied it to study deregulated events in HCV induced
HCC. Instead of comparing the gene expression profiles
of two consecutive stages, we overlaid gene expression
data with protein interaction networks to identify repre-
sentative subnetworks for each pathological stage and
deregulated subnetworks in disease progression. Our
study uncovered a temporal spectrum of functional
deregulation and prioritized key genes and pathways in
the progression of HCV induced HCC. Among them,
CDC2 was found to be a critical gene in the continuous
deregulation of the cell cycle in HCC progression. These
findings present a wealth of information for further
investigation.
Additional material
Additional file 1: Relationship of stepwise g values and network
scores. Red node is selected as cut-off for network identification. A,
Normal-Cirrhosis Network; B, Cirrhosis-Dysplasia Network; C, Dysplasia-
Early HCC Network; D, Early-Advanced HCC Network.
Additional file 2: Stage specific networks. Nodes represent gene
products and edges represent their interactions. Colour is scaled
according to gene expression fold change between two consecutive
stages.
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